OncoSil Gains FDA Humanitarian Device Exemption for Distal Cholangiocarcinoma: CancerNetwork | August 2026 | FDA Regulatory Update

Introduction:

Patients with unresectable, non-metastatic distal cholangiocarcinoma (dCCA) have limited locoregional treatment options. The FDA has granted a Humanitarian Device Exemption (HDE) to OncoSil, an EUS-delivered intratumoral radiation device, providing a new treatment option for selected patients when used as an adjunct to systemic therapy.

What is OncoSil?

OncoSil delivers phosphorus-32 (³²P) microparticles directly into the tumor through:

EUS-guided intratumoral injection → localized β-radiation → radiation delivery over approximately 3 months

The aim is to achieve sustained radiation within the tumor while limiting exposure to surrounding normal tissue.

Who Is Eligible?

The FDA HDE covers patients:

>21 years

With distal cholangiocarcinoma

With non-metastatic disease

Whose tumor is unresectable because it is locally advanced or because the patient is not a surgical candidate

Receiving the device as an adjunct to systemic therapy

Thus, this is not approval for metastatic cholangiocarcinoma and OncoSil is not intended to replace systemic therapy.

Why Is This Interesting for GI Practice?

Unlike conventional external-beam radiation, OncoSil brings radiation directly into the tumor using an interventional EUS platform.

This creates an interesting therapeutic convergence:

Advanced EUS + intratumoral brachytherapy-like radiation + systemic oncology

For therapeutic endoscopists, it represents another example of EUS evolving from a diagnostic and drainage platform toward direct delivery of antitumor therapy.

Important Regulatory Nuance: What Does HDE Mean?

This is a Humanitarian Device Exemption, which is different from conventional FDA device approval based on demonstration of effectiveness.

The HDE pathway is intended for devices targeting relatively rare diseases. The regulatory standard centers on safety and “probable benefit” outweighing risk, rather than the level of effectiveness evidence ordinarily required for standard premarket approval.

Therefore:

FDA HDE ≠ definitive evidence of survival benefit.

That distinction is important when communicating the significance of this approval.

What Happens Next?

US introduction will initially be tightly controlled:

Maximum 5 treatment centers

Operators must complete required training

FDA-mandated prospective post-approval study

Up to 30 patients

Follow-up over 24 months

Planned launch in the second half of 2027

The study is intended to further characterize safety and probable clinical benefit.

Clinical Impact:

For now, OncoSil should be viewed as a specialized multidisciplinary option for a narrowly defined population, rather than a new general standard for cholangiocarcinoma.

Appropriate selection will likely require collaboration among:

HPB oncology + therapeutic EUS + radiation oncology/nuclear medicine + hepatobiliary surgery

The most important future question is whether achieving greater local tumor control ultimately translates into clinically meaningful outcomes such as prolonged disease control, improved quality of life, conversion to resectability, or survival.

Bottom Line:

The FDA has granted OncoSil an HDE for EUS-guided intratumoral ³²P radiation in adults with unresectable, non-metastatic distal cholangiocarcinoma, as an adjunct to systemic therapy. It is an intriguing expansion of therapeutic EUS into direct cancer treatment—but the HDE designation should not be interpreted as proof of survival benefit. The forthcoming prospective post-approval study will be crucial in defining its real clinical role.